# MAP3K13 Antibody [clone 810CT26.6.1.1] (F55051)

| Catalog No. | Formulation | Size |
|---|---|---|
| F55051-0.4ML | In 1X PBS, pH 7.4, with 0.09% sodium azide | 0.4 ml |
| F55051-0.08ML | In 1X PBS, pH 7.4, with 0.09% sodium azide | 0.08 ml |

**Bulk quote request**

| | |
|---|---|
| **Availability** | 1-3 business days |
| **Species Reactivity** | Human |
| **Format** | Purified |
| **Host** | Mouse |
| **Clonality** | Monoclonal (mouse origin) |
| **Isotype** | IgM |
| **Clone Name** | 810CT26.6.1.1 |
| **Purity** | Purified |
| **UniProt** | O43283 |
| **Localization** | Cytoplasmic |
| **Applications** | Western Blot : 1:250-1:500<br>Immunofluorescence : 1:50-1:100 |
| **Limitations** | This MAP3K13 antibody is available for research use only. |



Immunofluorescent staining of human NCI-H460 cells with MAP3K13 antibody (green), DAPI nuclear stain (blue) and anti-Actin (red).



Immunofluorescent staining of human NCI-H460 cells with MAP3K13 antibody.



Immunofluorescent staining of human NCI-H460 cells with MAP3K13 antibody (green) and DAPI nuclear stain (blue).




Western blot testing of human NCI-H460 cell lysate with MAP3K13 antibody. Predicted molecular weight ~108 kDa.

## Description

Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

## Application Notes

The stated application concentrations are suggested starting points. Titration of the MAP3K13 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

## Immunogen

A portion of amino acids 52-305 from the human protein was used as the immunogen for the MAP3K13 antibody.

## Storage

Aliquot the MAP3K13 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.